A method for diagnosis of glaucoma comprising the steps of: (a) providing at least two samples comprising at least one at least partially purified ocular antigen, thereby providing together at least two at least partially purified ocular antigens or providing at least one sample comprising at least two at least partially purified ocular antigens wherein the at least two at least partially purified ocular antigens are selected from a Group 1 of ocular antigens comprising the following ocular antigens: actin, albumin, alpha-1-antitrypsin, annexin I-IV, annexin V, beta-2-adrenergic-receptor, brain derived neurotrophic factor (BDNF), calreticulin, cardiolipin, alpha-A-crystalline, alpha-B-crystalline, beta-L-crystalline, beta-S-crystalline, gamma-crystalline, DNA topoisomerase 1, fibronectin, α-fodrin (=spectrin), glial fibrillary acidic protein (GFAP), glutathion-S-Transferase, heat shock protein HSP10 (=chaperonin), HSP27, HSP60, HSP70, insulin, jo-1, lysozyme, myelin binding protein, myelin oligodrendrocyte glycoprotein, myoglobin, neuron specific enolase, neurotrophin 3, neurotrophin 4, neurotrophin 5, peroxide-dismutase, 3-phosphoserin, pre-albumin, protein kinase C inhibitor, protein kinase C, superoxid dismutase, alpha-synuclein, gamma-synuclein, thyreoglobulin, transferrin, transthyretin, topoisomerase-inhibitor, ubiquitin, vascular endothelial growth factor (VEGF), vimentin, (b) contacting a body fluid with the sample or samples provided in step a) comprising at least two at least partially purified ocular antigens, (c) detecting and/or quantifying the reactions of step b) between autoantibodies in the body fluid and the at least two partially purified ocular antigens in the sample or samples to determine an autoimmune reactivity value, (d) comparing measured autoimmune reactivity values with standard data obtained from glaucoma patients and optionally additionally from healthy individuals, to determine a glaucoma score and (e) optionally determine a diagnostic result by evaluation of the glaucoma score. (a) providing at least two samples comprising at least one at least partially purified ocular antigen, thereby providing together at least two at least partially purified ocular antigens or providing at least one sample comprising at least two at least partially purified ocular antigens wherein the at least two at least partially purified ocular antigens are selected from a Group 1 of ocular antigens comprising the following ocular antigens: actin, albumin, alpha-1-antitrypsin, annexin I-IV, annexin V, beta-2-adrenergic-receptor, brain derived neurotrophic factor (BDNF), calreticulin, cardiolipin, alpha-A-crystalline, alpha-B-crystalline, beta-L-crystalline, beta-S-crystalline, gamma-crystalline, DNA topoisomerase 1, fibronectin, α-fodrin (=spectrin), glial fibrillary acidic protein (GFAP), glutathion-S-Transferase, heat shock protein HSP10 (=chaperonin), HSP27, HSP60, HSP70, insulin, jo-1, lysozyme, myelin binding protein, myelin oligodrendrocyte glycoprotein, myoglobin, neuron specific enolase, neurotrophin 3, neurotrophin 4, neurotrophin 5, peroxide-dismutase, 3-phosphoserin, pre-albumin, protein kinase C inhibitor, protein kinase C, superoxid dismutase, alpha-synuclein, gamma-synuclein, thyreoglobulin, transferrin, transthyretin, topoisomerase-inhibitor, ubiquitin, vascular endothelial growth factor (VEGF), vimentin, (b) contacting a body fluid with the sample or samples provided in step a) comprising at least two at least partially purified ocular antigens, (c) detecting and/or quantifying the reactions of step b) between autoantibodies in the body fluid and the at least two partially purified ocular antigens in the sample or samples to determine an autoimmune reactivity value, (d) comparing measured autoimmune reactivity values with standard data obtained from glaucoma patients and optionally additionally from healthy individuals, to determine a glaucoma score and (e) optionally determine a diagnostic result by evaluation of the glaucoma score.